Search
Bazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalBazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. … In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as
Categories: Sex Hormones and Modulators of the Genital System, Estrogen Receptor ModulatorsOlanzapine
go.drugbank.com/drugs/DB00334ApprovedInvestigational[A177011] Olanzapine was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.[T548] … The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AntagonistsBenserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalA decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation … blood and to various extracerebral tissues.
Mixtures: MADOPAR 125 T, MADOPAR 125 TDipyridamole
go.drugbank.com/drugs/DB00975ApprovedInvestigationalDipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Mixtures: AGGRENOX ® CAPSULAS DE LIBERACION RETARDADAProducts: DIPIRIDAMOL GRAGEAS DE 75 MGIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalIn contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils … co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
Alverine
go.drugbank.com/drugs/DB01616ApprovedInvestigationalWithdrawnIt can also be used to help relieve period pain. … Alverine is a smooth muscle relaxant used to relieve cramps or spasms of the stomach and intestines. It is therefore useful in treating irritable bowel syndrome (IBS) and similar conditions.
Categories: Serotonin Receptor Antagonists, Serotonin 5-HT1 Receptor AntagonistsDolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalDolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative … This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AntagonistsNaloxone
go.drugbank.com/drugs/DB01183ApprovedInvestigationalVet approvedDue to its short duration of action, persons injected with naloxone should be monitored for responsiveness and potentially injected a second time or taken to the hospital. … [L33714,L33719] The primary purpose of including naloxone within Suboxone is to act as a deterrent to injection, as injected naloxone would rapidly reverse the effects of buprenorphine.
Mixtures: OSSICODONE E NALOXONE TEVA, OSSICODONE E NALOXONE TEVACategories: Peripheral Opioid Receptor AntagonistsOctamoxin
go.drugbank.com/drugs/DB09249ApprovedWithdrawnThis drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued. … Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome